2,4-thiazolidinedione has been researched along with Weight Gain in 9 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 7.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| " When administered to diabetic KKAy mice, T2384 rapidly improved insulin sensitivity in the absence of weight gain, hemodilution, and anemia characteristics of treatment with rosiglitazone (a TZD)." | 3.74 | T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. ( Chen, JL; Escaron, P; Furukawa, N; Learned, RM; Lee, G; Li, Y; Lindstrom, M; Liu, J; Liu, X; Plotnikova, O; Prasad, V; Walker, N; Wang, Z; Weiszmann, J; Xu, H, 2008) |
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 3.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Najmi, A | 1 |
| Alam, MS | 1 |
| Thangavel, N | 1 |
| Taha, MME | 1 |
| Meraya, AM | 1 |
| Albratty, M | 1 |
| Alhazmi, HA | 1 |
| Ahsan, W | 1 |
| Haque, A | 1 |
| Azam, F | 1 |
| Vallon, V | 1 |
| Hummler, E | 1 |
| Rieg, T | 1 |
| Pochynyuk, O | 1 |
| Bugaj, V | 1 |
| Schroth, J | 1 |
| Dechenes, G | 1 |
| Rossier, B | 1 |
| Cunard, R | 1 |
| Stockand, J | 1 |
| Choi, JH | 1 |
| Banks, AS | 1 |
| Kamenecka, TM | 1 |
| Busby, SA | 1 |
| Chalmers, MJ | 1 |
| Kumar, N | 1 |
| Kuruvilla, DS | 1 |
| Shin, Y | 1 |
| He, Y | 1 |
| Bruning, JB | 1 |
| Marciano, DP | 1 |
| Cameron, MD | 1 |
| Laznik, D | 1 |
| Jurczak, MJ | 1 |
| Schürer, SC | 1 |
| Vidović, D | 1 |
| Shulman, GI | 1 |
| Spiegelman, BM | 1 |
| Griffin, PR | 1 |
| Fonseca, V | 2 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| Li, Y | 1 |
| Wang, Z | 1 |
| Furukawa, N | 1 |
| Escaron, P | 1 |
| Weiszmann, J | 1 |
| Lee, G | 1 |
| Lindstrom, M | 1 |
| Liu, J | 1 |
| Liu, X | 1 |
| Xu, H | 1 |
| Plotnikova, O | 1 |
| Prasad, V | 1 |
| Walker, N | 1 |
| Learned, RM | 1 |
| Chen, JL | 1 |
| Fürnsinn, C | 1 |
| Brunmair, B | 1 |
| Meyer, M | 1 |
| Neschen, S | 1 |
| Furtmüller, R | 1 |
| Roden, M | 1 |
| Kühnle, HF | 1 |
| Nowotny, P | 1 |
| Schneider, B | 1 |
| Waldhäusl, W | 1 |
| Emilsson, V | 1 |
| O'Dowd, J | 1 |
| Wang, S | 1 |
| Liu, YL | 1 |
| Sennitt, M | 1 |
| Heyman, R | 1 |
| Cawthorne, MA | 1 |
| Scheen, A | 1 |
3 reviews available for 2,4-thiazolidinedione and Weight Gain
| Article | Year |
|---|---|
Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Topics: Adipose Tissue; Body Weight; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabetes Melli | 2003 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
Topics: Edema; Heart Failure; Humans; Hypoglycemic Agents; Safety; Thiazolidinediones; Weight Gain | 2004 |
[Glitazones and weight gain].
Topics: Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resis | 2002 |
6 other studies available for 2,4-thiazolidinedione and Weight Gain
| Article | Year |
|---|---|
Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Mice; Molecular Docking Simu | 2023 |
Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.
Topics: Animals; Epithelial Sodium Channels; Kidney Medulla; Kidney Tubules, Collecting; Mice; Patch-Clamp T | 2009 |
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Animals; Biphenyl Compounds; Body Fluids; Chloroceb | 2011 |
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Topics: Adipocytes; Adipogenesis; Animals; Benzothiazoles; Binding Sites; Cells, Cultured; Crystallography, | 2008 |
Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.
Topics: Animals; Biological Transport; Body Weight; Cell Line; Deoxyglucose; Glucose; In Vitro Techniques; I | 1999 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Protei | 2000 |